First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study

BACKGROUND: Subgroup analyses of clinical studies suggest that bevacizumab plus XELOX is effective and tolerable in elderly patients with metastatic colorectal cancer (mCRC). The prospective BECOX study examined the efficacy and safety of bevacizumab plus XELOX, followed by bevacizumab plus capecita...

Descripción completa

Detalles Bibliográficos
Autores principales: Feliu, J, Salud, A, Safont, M J, García-Girón, C, Aparicio, J, Vera, R, Serra, O, Casado, E, Jorge, M, Escudero, P, Bosch, C, Bohn, U, Pérez-Carrión, R, Carmona, A, Martínez-Marín, V, Maurel, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102952/
https://www.ncbi.nlm.nih.gov/pubmed/24946000
http://dx.doi.org/10.1038/bjc.2014.346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102952/
https://www.ncbi.nlm.nih.gov/pubmed/24946000
http://dx.doi.org/10.1038/bjc.2014.346

Ejemplares similares